Previous studies demonstrated that the anti-CD@ monoclonal antibody otelixizumab , administered at a total dose of @-@ mg , can slow the loss of C-peptide in recent-onset type @ diabetes patients , with frequent reactivation of Epstein Barr virus ( EBV ) .